ID-PRISM Center is a Collaborative Research and Educational Effort
ID-PRISM hosts meetings with Fred Hutch and University of Washington colleagues to share work in progress and provide training opportunities. The meetings over the next few months will focus on the challenges presented by the coronavirus SARS-CoV-2 and COVID-19 diseases. Our topics will include COVID-19 related biology, epidemiology, treatment, prevention and statistical modeling.
April 3, 2020
ID-PRISM Overview
Drs. Ying Qing Chen, Marco Carone and Alex Leudtke
Population-based assessment of epidemic spread, intervention and mobility effects, policy, advisory panels, social distancing
Dr. Elizabeth “Betz” Halloran
Addressing the COVID-19 Pandemic with CORE Protocols, based on Learnings from EVD
Dr. Thomas Fleming
Seattle Coronavirus Assessment Network (SCAN) COVID-19 (Adaptation of Seattle Flu Study)
Drs. Barbra Richardson and Jim Hughes
Designing COVID-19 prevention and treatment efficacy trials in the face of a rapidly evolving epidemic
Dr. Elizabeth Brown
Modeling of effectiveness of physical distancing interventions: delaying the epidemic or flattening the curve?
Dr. Laura Matrajt
Analysis of the early phase of COVID-19 outbreak in China
Drs. Yifan Zhu and Ying Qing Chen
Network and industry task force on clinical trials for COVID-19
Dr. Deborah Donnell
Quantification of SARS-Cov-2 viral load and diagnostics assays based on UW virology lab data
Dr. Leigh Fisher
World Health Organization Core Protocol for Preventive Vaccine Efficacy Trials
Drs. Yunda Huang, Holly Janes and Peter Gilbert
Risk assessment of accelerated pulmonary comorbidity following SARS-CoV-2 infection using host immune genetic polymorphism
Dr. Lue Ping Zhao
Immune correlates analysis, drug evaluation, and basic science of SARS-Cov-2
Dr. Paul Edlefsen
Survival analysis with doubly interval censored and truncated data for individual-level COVID-19 infection data
Drs. Gary Chan, Fei Gao and Kendrick Li
April 22, 2020
Multivariate Survival Analysis in the Design of COVID Vaccine Trials
Dr. Gary Chan
Evaluating the Effectiveness of Social Distancing Interventions Against COVID-19: Delaying the Epidemic or Flattening the Curve?
Dr. Laura Matrajty
May 20, 2020
This is part one of a two-part presentation. Part two was presented on May 27.
Issues in the Statistical Analysis of Vaccine Efficacy in COVID-19 Vaccine Efficacy Trials
Dr. Peter Gilbert
May 27, 2020
This is part two of a two-part presentation. Part one was presented on May 20.
Comparison of Statistical Methods for Assessing Vaccine Efficacy in COVID-19 Vaccine Efficacy Trials
Dr. Alex Luedtke
June 17, 2020
Clinical Trials for Prevention Interventions of COVID-19
Dr. Elizabeth Brown
September 30, 2020
Survival Analysis Using a 5-STAR Approach in Randomized Clinical Trials
Devab V. Mehrotra and Rachel Marceau West
Biostatistics and Research Decision Sciences, Merck
February 18, 2021
Evaluating Vaccine Efficcy of a Candidate HIV Vaccine vs. Counterfactual Placebo: Immune Marker Mediator Approach
Peter Gilbert, Ph.D.
Design for Actve-Arm Trial with Counterfactual Placebo Incidence Based on Recency Test
Fei, Gao, Ph.D.
Zoom Presentation: https://washington.zoom.us/rec/share/oRlGAm3mJCDNupkhgzcb37h8WQyjZCoEK5p3D4PYVVHbWUiM-ya303BnTRDvCpVO.XFPo9fgEMYn6vRHN
February 25, 2021
Estimation of Dapivirine Vaginal Ring Efficacy in the HOPE Trial
Dr. Alex Leudtke, Department of Statistics, University of Washington
A Bayesian Framework for Inferring Background HIV Incidence: An Application Using Tenofovir Drug Levels
Dr. David V. Glidden, Division of Biostatistics, University of California, San Francisco
PrEP Vacc: A Phase IIB Three-Arm, Two-Stage HIV Prophylactic Vaccine Trial with a Second Randomization to Compare TAF/FTC to TDF/FTC as Pre-Exposure Prophylaxis
Dr. Seila Kansiime, Medical Research Council / Uganda Virus Research Institute, Uganda
